RxDoctor Payments Data

Jiaul Ahsan, MD

Internal Medicine · Arlington, TXNPI 1114956877

Payments from drug & device makers

$1,587in general payments, 2019–2025

Across 17 payments — averaging $93.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceutical Holding Company Ltd.$1K
  • Pfizer$103
  • Astellas Pharma US Inc$31
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$30
  • Abbott$18
  • Novo Nordisk$14
  • plus $27 from 2 others

What the payments were for

  • Consulting fees$1,20076%
  • Food & beverage$38724%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,587 in reported general payments places this provider in the 75th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$211,585
Medicare patients
319
Services billed
2,390

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban44$45,228
JardianceEmpagliflozin34$42,111
OzempicSemaglutide16$24,171
MounjaroTirzepatide19$20,899
JanuviaSitagliptin Phosphate13$15,577
Combivent RespimatIpratropium/Albuterol Sulfate13$6,594
SymbicortBudesonide/Formoterol Fumarate24$5,696
LinzessLinaclotide11$5,661
Stiolto RespimatTiotropium Br/Olodaterol Hcl11$5,340
Breo ElliptaFluticasone/Vilanterol12$4,718
Albuterol Sulfate HfaAlbuterol Sulfate87$1,687
Atorvastatin Calcium188$1,378
Doxepin Hcl12$1,260
Levothyroxine Sodium101$1,077
Pantoprazole Sodium118$1,061

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$103$45,22844 claims
Novo NordiskOzempic$14$24,17116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Arlington

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →